Group 1 - Shares of Cars.com (CARS) have increased by 11.6% over the past four weeks, closing at $12.88, with a mean price target of $17.08 indicating a potential upside of 32.6% [1] - The mean estimate consists of six short-term price targets with a standard deviation of $5.02, where the lowest estimate is $12.00 (6.8% decline) and the highest is $25.00 (94.1% increase) [2] - Analysts show a consensus that Cars.com will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 0.8% over the past month, with one estimate increasing and no negative revisions [12] - Cars.com holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [14]

Sell-side analysts appear to have emerged as a more valuable resource for investors in India than in any other major market. To some observers, structural idiosyncrasies in the nation’s $5.4 trillion stock market are giving skilled stock-pickers an edge https://t.co/pJhqLYXPx7 ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $56.62, gaining 3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $96.69 indicates a 70.8% upside potential.The mean estimate comprises 26 short-term price targets with a standard deviation of $14.53. While the lowest estimate of $65.00 indicates a 14.8% increase from the current price level, the most optimistic ana ...

Group 1 - MongoDB (MDB) shares have increased by 10.5% over the past four weeks, closing at $209.2, with a mean price target of $280.88 indicating a potential upside of 34.3% [1] - The mean estimate is based on 33 short-term price targets with a standard deviation of $54.3, where the lowest estimate is $170.00 (indicating an 18.7% decline) and the highest is $430.00 (indicating a 105.5% increase) [2] - Analysts show strong agreement on MDB's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - Over the last 30 days, 11 earnings estimates for MDB have been revised higher, with no negative revisions, leading to a 15.8% increase in the Zacks Consensus Estimate [12] - MDB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Metsera Inc. (MTSR) shows significant upside potential with a mean price target of $55, indicating an 89.7% increase from its current price of $29.00 [1] Price Targets and Analyst Consensus - The average price target for MTSR ranges from a low of $38.00 to a high of $65.00, with a standard deviation of $14.8, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 31% increase, while the highest suggests a 124.1% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about MTSR's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.9%, with no negative revisions [12] - MTSR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Kimbell Royalty (KRP) shows potential for further upside, with a mean price target of $18.6 indicating a 27.3% upside from its current price of $14.61, following an 11.7% gain over the past four weeks [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $4.98, indicating variability among analysts; the lowest estimate is $12.00 (17.9% decline), while the highest is $24.00 (64.3% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about KRP's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 34.1%, with one estimate moving higher and no negative revisions [12] - KRP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead; empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Arcosa (ACA) closed at $87.00, with a 2.1% gain over the past four weeks, and a mean price target of $109.2 indicating a 25.5% upside potential [1] - The average price target ranges from a low of $100.00 to a high of $120.00, with a standard deviation of $7.29, suggesting a 14.9% to 37.9% upside [2] - Analysts show strong agreement on ACA's ability to report better earnings, with positive trends in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for ACA has increased by 1.1% due to one upward revision in earnings estimates over the last 30 days [12] - ACA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [14]

Group 1 - Copa Holdings (CPA) shares have increased by 5.4% over the past four weeks, closing at $107.42, with a mean price target of $152.73 indicating a potential upside of 42.2% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $19.78, where the lowest estimate of $125 suggests a 16.4% increase, and the highest estimate of $190 indicates a 76.9% surge [2] - Analysts show a strong consensus that CPA will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for CPA has increased by 1.9% due to three upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - CPA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13] - While price targets can be misleading, the direction indicated by the consensus price target may serve as a useful guide for potential price movements [10][11]

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has seen a significant stock price increase of 44.1% over the past four weeks, closing at $8.17, with analysts suggesting a potential upside to a mean price target of $18.90, indicating a 131.3% increase from the current price [1] Price Targets and Analyst Consensus - The average price target from analysts ranges from a low of $12 to a high of $25, with a standard deviation of $4.04, suggesting a potential increase of 46.9% to 206% from the current price level [2] - A low standard deviation indicates a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [2][9] Earnings Estimates and Market Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, five estimates for ORIC have increased, leading to a 12.6% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ORIC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]